2012 Biomet Company Profile & Analysis: Biologics Division

Date: October 1, 2011
Pages: 64
Price:
US$ 2,995.00 US$ 2,546.00
Offer valid until December 31, 2014!
License [?]:
Publisher: iData Research Inc.
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery
ID: 2D8F2319040EN
Leaflet:

Download PDF Leaflet

Biomet is one of the five largest orthopedic implant manufacturers in the world, with distribution in the U.S., Europe, Asia and a number of emerging markets. The company has also expanded into areas such as sports medicine and dental medical devices. Biomet's key joint reconstruction business unit accounted for the bulk of the company's revenues in the calendar year of 2011. Sports medicine and small joint reconstructive surgery were two of the fastest-growing areas for Biomet, both of which continued multi-year trends. However Biomet’s market share and areas of potential growth varied significantly by geographical region.

This report includes:
  • Company overview
  • Financial Metrics
  • Product Pipeline
  • SWOT Analysis
  • Market Shares by Country

The business units covered in this report include:
  • Bone Graft Substitutes
    • Allograft / DBM
    • Synthetic Bone Void Fillers
  • Cell Concentration
  • Hyaluronic Acid Viscosupplementation
EXECUTIVE SUMMARY

1.1 BIOMET OVERVIEW
1.2 CORPORATE REVENUE GROWTH BY BUSINESS UNIT
1.3 GLOBAL REVENUE BY REGION
1.4 MARKET SHARE: ORTHOPEDIC BIOMATERIALS

RESEARCH METHODOLOGY

2.1 IDATA’S 9-STEP METHODOLOGY
  2.1.1 Step 1: Project Initiation & Team Selection
  2.1.2 Step 2: Prepare Data Systems and Perform Secondary Research
  2.1.3 Step 3: Preparation for Interviews & Questionnaire Design
  2.1.4 Step 4: Performing Primary Research
  2.1.5 Step 5: Research Analysis: Establishing Baseline Estimates
  2.1.6 Step 6: Market Forecast and Analysis
  2.1.7 Step 7: Identify Strategic Opportunities
  2.1.8 Step 8: Final Review and Market Release
  2.1.9 Step 9: Customer Feedback and Market Monitoring

BIOMET COMPANY OVERVIEW

3.1 INTRODUCTION
3.2 COMPANY PROFILE
  3.2.1 Business Units
    3.2.1.1 Orthopedic Reconstruction
    3.2.1.2 Orthopedic Trauma, Spine and Biologics
    3.2.1.3 Sports Medicine
    3.2.1.4 Craniomaxillofacial
    3.2.1.5 Dental
3.3 GLOBAL REVENUES
  3.3.1 Global Revenues by Division
  3.3.2 Global Revenues by Geography
3.4 COMPANY HISTORY
3.5 COMPANY INFORMATION
  3.5.1 Size
  3.5.2 Office and Facility Locations

FINANCIAL METRICS

4.1 INCOME STATEMENT
4.2 BALANCE SHEET
  4.2.1 Balance Sheet
  4.2.2 Company Debt

PRODUCT PIPELINE

5.1 ORTHOPEDIC BIOMATERIALS
  5.1.1 U.S. FDA Investigational Device Exemption (IDE)
    5.1.1.1 Platelet Rich Plasmas for Tennis Elbow
  5.1.2 U.S. FDA Phase 1 Trials
    5.1.2.1 Bone Marrow Aspirate Concentration for Critical Limb Ischemia
  5.1.3 U.S. FDA 510(k) Submissions
    5.1.3.1 Bone Marrow Concentration System
  5.1.4 European CE Mark Trials
    5.1.4.1 ChonDux Trail Suspension
    5.1.4.2 Fat Concentration System

SWOT ANALYSIS

6.1 ORTHOPEDIC BIOMATERIALS SWOT ANALYSIS
  6.1.1 Strengths
    6.1.1.1 Joint Reconstruction
    6.1.1.2 History in Orthopedic Biologics
    6.1.1.3 Market Leader in Cell Concentration Systems
    6.1.1.4 Restructured Management
  6.1.2 Weaknesses
    6.1.2.1 Competition from Larger Competitors
    6.1.2.2 Lack of Advanced Bone Graft Substitute Product
    6.1.2.3 Partial Reliance on Distributors in the United States
    6.1.2.4 High Debt Levels
    6.1.2.5 Spine and Trauma Fixation Divisions
    6.1.2.6 Staff Restructuring
  6.1.3 Opportunities
    6.1.3.1 Undeveloped Asian and Emerging Markets Presence
    6.1.3.2 Underdeveloped Hyaluronic Acid Viscosupplementation Potential
    6.1.3.3 Migration to Chinese Manufacturing
  6.1.4 Threats
    6.1.4.1 Cost Control
    6.1.4.2 Medical Conservatism
    6.1.4.3 Department of Justice Sanction
    6.1.4.4 European Sovereign Debt Crisis of 2010 and Onward
    6.1.4.5 Potential for Acquisition

ORTHOPEDIC BIOMATERIALS MARKET SHARE

7.1 MARKET INTRODUCTION
  7.1.1 Bone Graft Substitutes
    7.1.1.1 Introduction
    7.1.1.2 Indications
    7.1.1.3 Materials
  7.1.2 Cell Concentration
    7.1.2.1 Introduction
    7.1.2.2 Platelet Rich Plasma
    7.1.2.3 Bone Marrow Aspirate
  7.1.3 Hyaluronic Acid Viscosupplementation
    7.1.3.1 Introduction
    7.1.3.2 Benefits of Viscosupplementation
    7.1.3.3 Synovial Fluid
    7.1.3.4 Three-Injection Cycle Products
    7.1.3.5 Five-Injection Cycle Products
    7.1.3.6 Single-Injection Cycle Products
7.2 KEY PRODUCTS
  7.2.1 Bone Graft Substitutes
    7.2.1.1 Allograft / DBM
    7.2.1.2 Synthetic Bone Void Fillers
  7.2.2 Hyaluronic Acid Viscosupplementation
  7.2.3 Cell Concentration
7.3 MARKET SHARE AND REVENUE ANALYSIS
  7.3.1 Bone Graft Substitutes
    7.3.1.1 Global Market Share
    7.3.1.2 United States Market Share
    7.3.1.3 European Market Share
      7.3.1.3.1 European Market Share by Country (Germany, France, U.K., Spain, Italy, Benelux, Scandinavia, Switzerland, Austria, Portugal and Greece)
    7.3.1.4 International Market Share
  7.3.2 Cell Concentration (Platelet and Bone Marrow)
    7.3.2.1 Global
    7.3.2.2 U.S. Market Share
    7.3.2.3 European and International Market Share
  7.3.3 Hyaluronic Acid Viscosupplementation
    7.3.3.1 Global
    7.3.3.2 U.S. Market Share
    7.3.3.3 European Market Share
    7.3.3.4 International Market Share

ABBREVIATIONS

LIST OF FIGURES

EXECUTIVE SUMMARY

RESEARCH METHODOLOGY

BIOMET COMPANY OVERVIEW

Figure 3-1: Global Revenues by Division, Biomet, (US$M), 2010 – 2011
Figure 3-2: Global Revenues Growth by Division, Biomet, 2011
Figure 3-3: Global Revenues by Geography, Biomet, (US$M), 2010 – 2011
Figure 3-4: Global Revenues by Geography, Biomet, 2011
Figure 3-5: Company Size, Biomet, 2011
Figure 3-6: Key Facilities, Biomet, 2011

FINANCIAL METRICS

Figure 4-1: Income Statement, Biomet, 2009 – 2011 (US$M)
Figure 4-2: Balance Sheet, Biomet, 2009 – 2011 (US$M)
Figure 4-3: Company Debt, Biomet, 2011 (US$M)

PRODUCT PIPELINE

SWOT ANALYSIS

ORTHOPEDIC BIOMATERIALS MARKET SHARE

Figure 7-1: Bone Graft Substitutes Market Share, Biomet, 2011 (US$M)
Figure 7-2: Bone Graft Substitutes Market Share by Country, Europe, Biomet, 2011 (US$M)
Figure 7-3: Cell Concentration Market Share, Biomet, 2011
Figure 7-4: Hyaluronic Acid Viscosupplementation Market Share by Country, Biomet, 2011 (US$M)

ABBREVIATIONS

LIST OF CHARTS

EXECUTIVE SUMMARY

Chart 1-1: Business Unit Revenue by Percentage, Biomet, 2011
Chart 1-2: Annual Revenue Growth by Business Unit, Biomet, 2011
Chart 1-3: Percentage of Global Revenues by Region, Biomet, 2011
Chart 1-4: Global Biomaterials Market Share, Biomet, 2011

RESEARCH METHODOLOGY

BIOMET COMPANY OVERVIEW

Chart 3-1: Global Revenues by Division, Biomet, 2011
Chart 3-2: Global Revenue Growth by Division, Biomet, 2011

FINANCIAL METRICS

PRODUCT PIPELINE

SWOT ANALYSIS

ORTHOPEDIC BIOMATERIALS MARKET SHARE

Chart 7-1: Bone Graft Substitutes Market Share, Biomet, 2011
Chart 7-2: Cell Concentration Market Share, Biomet, 2011
Chart 7-3: Hyaluronic Acid Viscosupplementation Market Share by Country,
Europe, Biomet, 2011

ABBREVIATIONS

Ask Your Question

2012 Biomet Company Profile & Analysis: Biologics Division
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: